CN1110554A - Ulcer suppository - Google Patents
Ulcer suppository Download PDFInfo
- Publication number
- CN1110554A CN1110554A CN 94111734 CN94111734A CN1110554A CN 1110554 A CN1110554 A CN 1110554A CN 94111734 CN94111734 CN 94111734 CN 94111734 A CN94111734 A CN 94111734A CN 1110554 A CN1110554 A CN 1110554A
- Authority
- CN
- China
- Prior art keywords
- colitis
- hydrocortisone
- suppository
- medicine
- grams
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The suppository for colitis or rectitis is prepared with hydrocortisone as main component, oil-soluble semi-sythesized fatty glyceride as excipient, and sodium pyrosulfite and/or disodium of complexon as stabilizer and features high medicinal concentration of affected position, high curative effect, low cost and no by-effect.
Description
The invention belongs to the medicine for external use of treatment chronic colitis, proctitis ulcerosa, straight second colitis, is to be the suppository of principal agent with the hydrocortisone.
Influence commonly encountered diseases, the frequently-occurring disease-chronic colitis of human health, especially chronic ulcerative proctitis, straight second colitis sickness rate 8/10000ths to ten, also can be with regard to the trend that sickness rate in the worldwide changes with growth in the living standard, the variation of life style and increasing gradually, chronic ulcerative colitis has characteristics such as course of disease length and spontaneous outbreak, and the cause of disease is owed clearly, and treatment lacks specificity.At present to the healing measure of this disease mainly with controlling symptoms, prevent that recurrence from being purpose.Common drug has salicylic acid, corticosteroid etc., and there is following shortcoming in this class medicine: systemic administration will reach high local concentrations, needs dosage big, and administration time is long, often cause whole body side effect in various degree, and therapeutic effect is bad.The external compound preparation that hydrocortisone is still arranged, but still be systemic administration, this medicine prescription is complicated, and drug content is few, and the affected part drug level is not high, and curative effect is unclear, so be not widely used.
The purpose of this invention is to provide a kind of easy to usely, patient easily accepts, cheap, to good ulcer suppositories of therapeutic effect such as chronic colitis, proctitis ulcerosa, straight second colitis.
The present invention act as the basis with the antiinflammatory of hydrocortisone, antiallergic etc., consider that this course of disease is long, systemic administration does not reach high local concentrations, and should mainly rely on form and the partial high concentration of medicine in local activation by the disease therapeutical effect, and irrelevant with the drug plasma level.The local application of colitis, medicine directly acts on local organization, impels pathological tissues to repair relief of symptoms.
Structure and chemical property instructions for use according to hydrocortisone, select for use the substrate with its compatibility that the effect of the drug release of obstruction should be arranged, the speed that the medicine that slows down discharges from substrate, thereby reach persistent local action, because hydrocortisone is water insoluble, after from oil-soluble substrate, slowly discharging, also be difficult in the aqueous juice of intestinal, shifting, it is slower that principal agent is absorbed, thereby reach the requirement of hydrocortisone as local application.By the radioisotope scanning experiment confirm, every bolt of this medicine weighs 1.37 grams, is enough to cover the straight colonic pathological change tissue below 60 centimetres, has designed dosage form of the present invention and prescription composition thus.
The present invention adopts suppository formulation.Prescription is formed: with single hydrocortisone is principal agent, and the oil-soluble semi-synthetic fatty acid glyceride is an excipient, and sodium pyrosulfite and/or disodiumedetate are stabilizing agent.
The ulcer suppository prescription is:
Hydrocortisone 10～30 grams,
Semi-synthetic fatty acid glyceride 1200～2000 grams,
Sodium pyrosulfite
(and/or disodiumedetate)〉account for substrate amount 0.1%～0.8%,
Make 1000
Major advantage is: this suppository topical, and medicine directly acts on local organization, and the affected part drug level is big, impels the pathological tissues reparation to alleviate, and has no side effect, and therapeutic effect is good.Said preparation is easy to use, and the patient easily accepts, and overcome enema and used inconvenience, the shortcoming that oral side effect is big, cheap, good use prospect and social benefit are arranged.
Technological process is as follows:
Hydrocortisone raw material fine powder → antioxidant (
) → stir evenly → add melted filtering semi-synthetic fatty acid glyceride → stir evenly → injection molding → scrape mould → cooling → demoulding → quality examination → packing.
Embodiment: ulcer suppository adopts
Hydrocortisone 20 grams,
Disodiumedetate 1.37 grams,
Sodium pyrosulfite 1.37 grams,
Semi-synthetic fatty acid glyceride 1370 grams,
Make 1000
Claims (2)
1, a kind of medicine for external use for the treatment of chronic colitis, proctitis ulcerosa, straight second colitis, it is characterized in that: dosage form is a suppository, with single hydrocortisone is principal agent, and the oil-soluble semi-synthetic fatty acid glyceride is an excipient, and sodium pyrosulfite and/or disodiumedetate are that stabilizing agent is formed.
2, the medicine for external use by the said treatment chronic colitis of claim 1, proctitis ulcerosa, straight second colitis is characterized in that: hydrocortisone 10～30 grams in per 1000 suppositorys, semi-synthetic fatty acid glyceride 1200～2000 grams, sodium pyrosulfite and/or disodiumedetate respectively account for substrate amount 0.1%～0.8%, and blending forms.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 94111734 CN1110554A (en) | 1994-04-28 | 1994-04-28 | Ulcer suppository |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 94111734 CN1110554A (en) | 1994-04-28 | 1994-04-28 | Ulcer suppository |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1110554A true CN1110554A (en) | 1995-10-25 |
Family
ID=5035572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 94111734 Pending CN1110554A (en) | 1994-04-28 | 1994-04-28 | Ulcer suppository |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1110554A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100421648C (en) * | 2006-08-15 | 2008-10-01 | 苏州市立医院 | Hydrocortisone clyster agent and method for preparing the same |
| CN106896242A (en) * | 2015-12-18 | 2017-06-27 | 中芯国际集成电路制造(上海)有限公司 | Probe test attachment means |
-
1994
- 1994-04-28 CN CN 94111734 patent/CN1110554A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100421648C (en) * | 2006-08-15 | 2008-10-01 | 苏州市立医院 | Hydrocortisone clyster agent and method for preparing the same |
| CN106896242A (en) * | 2015-12-18 | 2017-06-27 | 中芯国际集成电路制造(上海)有限公司 | Probe test attachment means |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69434490T2 (en) | Compilations for cancer treatment | |
| US5510384A (en) | Method of treating damaged mucosal and epithelial tissues with misoprostol | |
| Drucker et al. | Antiplatelet therapy in atrophie blanche and livedo vasculitis | |
| EP0502925B1 (en) | Composition for treating inflammatory bowel disorders | |
| JPS6038324A (en) | Fatty acid composition | |
| JP2008542324A (en) | Mucoadhesive xyloglucan-containing preparations useful in medical devices and pharmaceutical preparations | |
| Ziskin et al. | Chronic desquamative gingivitis: A report of twelve cases | |
| IE903302A1 (en) | Topical preparation for treatment of aphthous ulcers and¹other lesions | |
| EP2034956A1 (en) | Compositions comprising glycosaminoglycans of low viscosity and use of said composition in therapy of chronic cystitis | |
| US4910224A (en) | Method of modifying the lipid structure and function of cell membranes and pharmaceutical compositions for use therein | |
| WO1996004912A1 (en) | Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes | |
| CN108324739B (en) | Pharmaceutical composition and application thereof, oral cleaning and nursing product, oral health product and medicine | |
| WO2019134159A1 (en) | Rectal mucosal administration preparation of pulsatilla chinensis (bge.) regel saponin b4 and preparation method therefor | |
| CN1110554A (en) | Ulcer suppository | |
| Rothwell et al. | Does fish oil benefit stone formers? | |
| WO2000044390A1 (en) | Treatment of bladder and gastrointestinal mastocytosis | |
| Kupferman et al. | Prolongation of anti-inflammatory effect of prednisolone acetate: Influence of formulation in high-viscosity gel | |
| Swell et al. | Influence of bile acids on biliary lipid excretion in man: Implications in gallstone formation | |
| Sauerbruch et al. | Effect of endoscopic sphincterotomy on bile acid pool size and bile lipid composition in man | |
| EP0238198A2 (en) | Method of modifying the lipid structure function and expression of cell membranes and pharmaceutical compositions for use therein | |
| CN1045382C (en) | Runshu eye drops and making method thereof | |
| RU2058783C1 (en) | Agent for mouth mucosa treatment | |
| CN1101276A (en) | External-use medicine composition for vaginitis | |
| King et al. | The effect of atropine sulfate, morphine sulfate, pilocarpine hydrochloride, prostigmine methylsulfate, sodium salt of dehydrocholic acid and secretin on the gastric and duodenal secretions of normal persons when fasting | |
| US3461208A (en) | Indomethacin compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |